CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 7,137	$ 20,968	$ 41,867
Operating expenses:
Cost of goods sold	620	6,174	7,266
Research and development	32,805	108,510	91,879
General and administrative	26,530	27,779	30,257
Restructuring	5,565
Total operating expenses	65,520	142,463	129,402
Operating loss	(58,383)	(121,495)	(87,535)
Other income, net	2,828	3,586	2,061
Impairment of long-lived assets	(4,274)	0	0
Inventory write-down	(2,963)
Non-cash interest expense on liability related to sales of future royalties and milestones	(8,473)	(604)
Loss before benefit from income taxes	(71,265)	(118,513)	(85,474)
Benefit from income taxes	398	0	0
Net loss	$ (70,867)	$ (118,513)	$ (85,474)
Net loss per share:
Basic (in dollars per share)	$ (15.53)	$ (26.26)	$ (19.12)
Diluted (in dollars per share)	$ (15.53)	$ (26.26)	$ (19.12)
Weighted average shares:
Basic (in shares)	4,562,738	4,512,422	4,471,130
Diluted (in shares)	4,562,738	4,512,422	4,471,130
Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities	$ 260	$ 1,412	$ (1,314)
Total comprehensive loss	(70,607)	(117,101)	(86,788)
Collaborative revenue
Revenue:
Total revenue	2,086	12,936	16,572
Commercial supply revenue
Revenue:
Total revenue	640	5,843	10,223
License and milestone fees
Revenue:
Total revenue		910	15,000
Royalty revenue
Revenue:
Total revenue		415	$ 72
Clinical compound revenue
Revenue:
Total revenue	84	165
Other revenue
Revenue:
Total revenue	$ 4,327	$ 699